COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Continuous Local Anesthetic and Steroid Infusion in Abdominal Surgery (GR-CWI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02002663
Recruitment Status : Completed
First Posted : December 6, 2013
Last Update Posted : March 3, 2017
Information provided by (Responsible Party):
Massimo Allegri, IRCCS Policlinico S. Matteo

Brief Summary:

The aim of the study is the identification, comparing continuous infusion of local anesthetics and steroids intralesionally with the current gold standard therapy (PCA), of the effective dose of local anesthetics and steroids within 7 days following abdominal surgery in order to halve the consumption of opioids and give the best pain control with a lower incidence of side effects and persistent chronic pain (at 1 and 3 months) We also plan to measure the peripheral inflammation and oxidative stress by analyzing the pro-inflammatory cytokines and anti-inflammatory properties.

Another objective is to investigate the combined effect of polymorphisms of genes related to pain sensitivity, and the correlation with the development of the inflammatory response and the incidence of chronic post-surgical pain (CPSP), which will be considered to validate the genotype-phenotype correlations.

The intralesional catheter will be placed within the operating field by the surgeon at the end of the procedure.

  • first postoperative 24 hours: ropivacaine 0.2%-methylprednisolone 1 mg/kg/die infusion (10ml/h) in the wound. Rescue dose with morphine via intravenous PCA (0.5 mg/ml, bolus 1 mg, lock-out 5 min, max 20 mg in 4 hours)
  • from 24 hs to 48 hs: ropivacaine 0.2%-methylprednisolone 1 mg/kg/die infusion (10ml/h) or saline 0.9% 10 ml/h in the wound. Rescue dose with morphine via intravenous PCA (0.5 mg/ml, bolus 1 mg, lock-out 5 min, max 20 mg in 4 hours) . from 48 hs to 7th day: ropivacaine 0.2% or saline 0.9% via patient controlled intralesional analgesia (PCIA) (2 mg/ml, bolus 20 mg, lock-out 60 min, max 80 mg in 4 hours). Rescue dose Tramadol 100 mg.

The first assessment will be by the anesthetist pre-operatively, to verify the patient eligibility.

All patients will be evaluated at the end of surgery (T0) and after 3-6-12-24-36-48 hours after surgery. Further evaluations are scheduled every 24 hours until the seventh postoperative day. At each assessment will be recorded: Numeric Rating Scale (NRS) at rest, NRS at movement (NRSm) - defined as pain at deep inspiration and cough - ; blood pressure, heart rate, respiratory rate, nausea (PONV scale), need of rescue analgesics and presence of any complications.

On the 7th postoperative day, the patient will be reassessed by both pain clinicians and surgeon; the surgeon will remove the catheter.

At 1 month and 3 months after surgery, the patient will be evaluated through phone interview to investigate pain persistence.

Inflammatory response analysis will be performed on the first 15 patients in each group (for a total of 30 patients). Before awakening of the patient the surgeon will insert a microdialysis catheter in the fat adjacent to the surgical wound with sterile technique. The microdialysed liquid will be collected in dedicated tubes directly in the infusion pump. The sample of the first hour will be discarded to avoid that microtrauma of catheter positioning influences the study. Sampling will be performed every 6 hours the first day, and every 12 hours in the second and third day. Serum samples will be collected to compare systemic with regional samples. All samples will be stored at -80 ° C until sampling. Concentrations quantification of different cytokines will be analyzed by ELISA Parma Unit will analyze VNTR (variable number of tandem repeats) polymorphism of the ADRB2 gene, directly related to the risk of chronic persistent postoperative pain development; Pavia Unit will take care of genotyping of polymorphic sites in the following genes: OPRM1 (mu-opioid receptor 1), COMT (catecholamine O-methyl transferase), UGT2B7 (UDP-glucuronyl transferase), IL1Ra (interleukin 1receptor alpha). From the blood samples will be extracted DNA and RNA using standard procedures. RNA will be retained for possible future studies on the expression of genes of interest. The DNA will be used instead for the study of genetic polymorphisms.

In this study the formation of free radicals, particularly superoxide will be assessed together with lipid peroxidation in both serum and urine, The 8- deoxyguanosine and Poly-ADP-ribose polymerase (PARP), the presence of nitrotyrosine.

Blood samples and urine tests will be carried out before the start of surgery , before the bolus of morphine and local anesthetic , at 24 h after the end of the intervention and 48 h after end of the intervention

Condition or disease Intervention/treatment Phase
Abdominal Pain Drug: ropivacaine 0.2% Drug: Methylprednisolone 1mg/kg Drug: saline 0.9% Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of the Intralesional Infusion of Local Anesthetic and Steroids After Major Abdominal Surgery: a Randomized Double Blind Phase III Trial
Study Start Date : August 2013
Actual Primary Completion Date : June 2016
Actual Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Abdominal Pain

Arm Intervention/treatment
Experimental: ropivacaine + methylprednisolone
Continuous infusion of Ropivacaine 0.2% and methylprednisolone 1mg/kg 10ml/h through intralesional catheter for 24 hours
Drug: ropivacaine 0.2%
PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
Other Name: morphine PCA

Drug: Methylprednisolone 1mg/kg
Placebo Comparator: saline
Continuous infusion of saline through intralesional catheter for 24 hs
Drug: saline 0.9%

Primary Outcome Measures :
  1. total morphine consumption [ Time Frame: 7 days after surgery ]

Secondary Outcome Measures :
  1. pain values [ Time Frame: 7 days ]
    number of patients presenting NRS values lower than 4 both at rest and at movement

  2. number of patients presenting methylprednisolone side effects [ Time Frame: up to 7 days ]
    wound healing retardation or other side effects which could be related to steroid wound infusion

  3. number of patients presenting morphine or ropivacaine side effects [ Time Frame: up to 7 days ]
    incidence of PONV, pruritus and sedation; side effects related to local anesthetic's systemic absorption

  4. persistent pain at 1 and 3 months [ Time Frame: 3 months ]
    number of participants developing pain at 1 and 3 months after surgery

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and females 18-85 years old scheduled to use PCA with morphine for postoperative pain control
  • HIV-negative
  • Classification American Society of Anesthesiologists (ASA) I: without systemic disease
  • Classification ASA II or III (moderate systemic disease or severe systemic disease that limits activity without disability)
  • Scheduled for major abdominal and urologic surgery (no emergency surgery)

Exclusion Criteria:

  • regular use of opioid analgesics;
  • History of abuse of drugs and / or alcohol;
  • Postoperative hospitalization in intensive care with sedation and / or mechanical ventilation;
  • severe renal impairment (creatinine> 2 g / dl, creatinine clearance <30 ml / h) and / or hepatic impairment (cholinesterase <2000 IU);
  • Cardiac disorders (arrhythmias, heart failure);
  • Neurological disorders (epilepsy);
  • Cognitive disorders, mental retardation, psychiatric disorders;
  • Changes in the normal coagulation or coagulopathy (INR> 2, PTT> 44 sec);
  • Platelet count less than 100.000/mm3;
  • BMI> 30;
  • Allergy to study drugs.
  • diabetes type I/II

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02002663

Layout table for location information
•2nd Service of Anesthesia, Intensive Care and Pain Therapy, University Hospital of Parma
Parma, Italy, 43126
Department of Anesthesia and ICU, General Surgery and Urology, S Matteo Hospital
Pavia, Italy, 27100
Sponsors and Collaborators
IRCCS Policlinico S. Matteo
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Massimo Allegri, MD, IRCCS Policlinico S. Matteo Identifier: NCT02002663    
Other Study ID Numbers: PT-SM-13- YR FIRST STEP CWI-PP
First Posted: December 6, 2013    Key Record Dates
Last Update Posted: March 3, 2017
Last Verified: March 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Abdominal Pain
Neurologic Manifestations
Signs and Symptoms, Digestive
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anesthetics, Local
Anti-Inflammatory Agents
Autonomic Agents
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents